Patents Assigned to Novartis AG
  • Patent number: 11987644
    Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: May 21, 2024
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Tina Buch, Christian Graf, Daniel Heitmann, Thomas Jostock, Hans-Peter Knopf, Rolf Koehler, Jiri Kovarik, Stephen John Oliver, Dhavalkumar Patel, Maximilian Woisetschlaeger
  • Patent number: 11981731
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: May 14, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Patent number: 11975026
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 7, 2024
    Assignee: Novartis AG
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • Patent number: 11970497
    Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: April 30, 2024
    Assignee: Novartis AG
    Inventors: Chris Adair, Tracy Chen, Jian Ding, Christy Fryer, Yuko Isome, Marie-Helene Larraufie, Katsumasa Nakajima, Nik Savage, Ariel Sterling Twomey
  • Patent number: 11970525
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: April 30, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG, The Scripps Research Institute
    Inventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
  • Patent number: 11963999
    Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: April 23, 2024
    Assignee: Novartis AG
    Inventors: John Louis Diener, Jiaping Gao, Rick Jerome Schiebinger
  • Patent number: 11958846
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: April 16, 2024
    Assignee: Novartis AG
    Inventors: Christopher Adair, Katsumasa Nakajima, Rukundo Ntaganda, Julien Papillon, Troy Douglas Smith
  • Patent number: 11958805
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 16, 2024
    Assignee: NOVARTIS AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11952428
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: April 9, 2024
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • Patent number: 11952386
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • Patent number: 11951190
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 11951101
    Abstract: Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: April 9, 2024
    Assignee: Novartis AG
    Inventors: Irina Baltcheva, Peter End, Julie Marie-Pomme Gabrielle Milojevic
  • Patent number: 11944602
    Abstract: The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: April 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Eric Legangneux, Alexandros Sagkriotis, Pierre Jordaan, Florine Polus, Alan John Camm, Shibadas Biswal, Parasar Pal, Uday Kiran Veldandi, Atul Keshav Pawar, Vassilios Aslanis, Kasra Shakeri-Nejad
  • Patent number: 11945859
    Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: April 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Juergen Sigg, Pamela De Moor
  • Patent number: 11944664
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: April 2, 2024
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Patent number: 11939389
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • Patent number: 11939397
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Michael Didonato, Christoph Erkel, Anna Galkin, Scott Glaser, Klaus Felix Hartlepp, Yong Jia, Alexandra Kraus, Christian Cho-Hua Lee, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler
  • Patent number: 11931430
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 11930837
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • Patent number: 11931363
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao